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Introduction
Antineoplastic  platinum  complexes  are  widely  used 
to treat several human malignancies. Cisplatin, a first-gen-
eration platinum complex, has been successfully used for 
treatment of several types of cancer, including testicular, 
head and neck, ovarian, cervical and nonsmall cell lung car-
cinoma1–4. Although the precise mechanism has not been 
fully elucidated, the possible mechanisms involved in the 
anticancer activity of cisplatin are becoming clearer. Cis-
platin directly binds to the DNA of tumor cells, forming a 
cross-link that leads to the arrest of DNA synthesis and rep-
lication. In the case of rapidly dividing cells such as cancers, 
cisplatin can also induce DNA damage, which ultimately 
leads to irreversible cellular injury and death.
Unfortunately, cisplatin treatment causes several types 
of side effects due to the drug’s lack of target selectivity. The 
major limiting factors in the use of cisplatin are neurotoxici-
ty, ototoxicity, nausea, vomiting and nephrotoxicity. Among 
these factors, the prevalence of nephrotoxicity is extremely 
high, occurring in about one-third of patients undergoing 
cisplatin treatment5–7. Nephrotoxicity is therefore regarded 
as the most common and serious side effect of cisplatin che-
motherapy8–10.
Over the last two decades, hundreds of platinum com-
plexes have been synthesized and tested to lessen the ad-
verse effects as well as to improve the effectiveness of these 
antineoplastic agents11,12. Dose-limiting nephrotoxicity has 
been a critical concern in the selection of new drug candi-
dates during the early stages of drug development. Several 
novel cisplatin analogues have been identified that exhibit 
less severe side effects without sacrificing their beneficial 
effects. Nedaplatin is one of the second-generation platinum 
complexes with reduced nephrotoxicity and may serve as 
a substitute for cisplatin or even surpass cisplatin for use 
in combination with other drugs. Nedaplatin’s spectrum of 
activity largely overlaps that of cisplatin, as the drug is ac-
tive against various solid tumors, including lung cancer13, 
esophageal cancer14, head and neck cancer15, testicular can-
cer16 and ovarian cancer17. However, nedaplatin also causes 
nephrotoxicity at doses that are therapeutic in humans. In 
this review, we summarize recent findings concerning the 
renal histopathology and molecular pathogenesis induced 
by antineoplastic platinum complexes, with a particular fo-
cus on the comparative nephrotoxicity of cisplatin and neda-
platin in rats.
Renal Histopathology
Comparative nephrotoxicity of cisplatin and nedaplatin
Toxicity target and histopathological characteristics in 
cisplatin and nedaplatin nephrotoxicity are summarized in 
Table 1. Renal tubular cell death is a common histopatho-
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logical feature associated with nephrotoxicity induced by 
antineoplastic platinum complexes. In in vivo animal mod-
els, cisplatin primarily damages the proximal tubule, spe-
cifically the S3 segment of the proximal tubule in the outer 
medullary stripe18–20. The histopathological characteristics 
of cisplatin nephrotoxicity in rats are massive necrosis and 
subsequent regeneration of renal proximal tubular cells21–23. 
In contrast, renal papillary injury is reported to be minor, 
and  the  glomerulus  undergoes  no  obvious  morphologic 
changes24,25. Long-term cisplatin treatment causes cyst for-
mation and interstitial fibrosis in the kidney22.
In contrast to cisplatin nephrotoxicity, nedaplatin pri-
marily affects the renal papilla in rats23.  Papillary injury 
induced by nedaplatin is morphologically characterized by 
hyaline droplet changes, apoptosis or regenerative hyperpla-
sia of the collecting duct epithelium and the epithelium cov-
ering the renal papilla. These adverse changes in the renal 
papilla tend to be greater toward the tip. In severe cases, 
papillary necrosis also occurs. Ultrastructural features in 
combination with a positive reaction to acid phosphatase 
confirm that the hyaline droplets associated with nedapla-
tin nephrotoxicity are hyperplastic lysosomes. In the cortex, 
only slight necrotic and degenerative changes are observed, 
such as slight focal tubular necrosis, regeneration and dil-
atations lined with a flattened epithelium in the proximal 
and distal tubule. The glomerulus shows no obvious toxic 
changes.
Time course of the changes of nedaplatin nephrotoxicity
We also characterized the temporal changes in neda-
platin nephrotoxicity in rats26. The early stage of nedaplatin-
induced nephrotoxicity in rats is characterized by apoptosis, 
with shrunken cytoplasm and pyknotic/fragmented nuclei 
in the collecting duct epithelial cells and proximal and dis-
tal tubular cells. Four days after nedaplatin dosing, a small 
number of cortical tubules exhibit focal necrosis, and are 
filled with debris derived from necrotic and/or apoptotic 
cells. The cortical tubule also exhibits a degenerative ap-
pearance and is characterized by loss of brush borders and 
abnormally large vacuoles in the cytoplasm. In the period 4 
to 7 days following nedaplatin treatment, cystic dilatation 
and regeneration of the renal tubules occur, with atypical 
nuclei in the renal cortex. In the collecting duct epithelium, 
morphological regenerative changes reflecting the tubular 
injury occur and are characterized by protrusion into the 
collecting duct lumen of enlarged cells with atypical nuclei. 
Characteristic  papillary  necrosis  is  also  observed  in  the 
tip of renal papilla 4 or more days after a single nedaplatin 
dose24,26,27. In the later stage of nedaplatin-induced nephro-
toxicity, subsequent cystic dilatation and regeneration occur 
in the affected tubules, but incomplete tissue repair is still 
observed 2 weeks after treatment.
Pathogenesis of Nephrotoxicity
Renal uptake and accumulation
To exert cytotoxic activity, the platinum complex must 
enter a cell. Cisplatin is preferentially taken up by the highly 
susceptible proximal tubular cells within the S3 segment, 
the principal site of acute injury in the kidney18–20. Safirst-
ein et al.28 demonstrated renal preference in the accumula-
tion of cisplatin; in renal tissue slices, they found cisplatin 
at concentrations up to five-fold above the concentration in 
the medium. Safirstein et al. also demonstrated that the kid-
ney accumulates platinum in part by transport or specific 
binding to components of the kidney transport system and 
then biotransforms the platinum intracellularly. Preferential 
injury to the proximal tubule could therefore be explained 
by the propensity of cisplatin to accumulate in this tissue.
Although the precise mechanisms involved in the in-
tracellular transport systems of platinum complexes are un-
clear, several reports have discussed the cellular uptake of 
platinum complexes under both in vitro and in vivo condi-
tions. In the case of cancer cells, about half of the cispla-
tin taken up is due to passive diffusion through the plasma 
membrane, and uptake of the remaining half is mediated 
by several factors, including transporters29. A high-affinity 
copper transporter, Ctr1, is believed to play a role in cis-
platin uptake in cancer cells. Recent works clearly indicate 
that Ctr1 protein localizes mainly on the basolateral side of 
tubular cells in the kidney and contributes to cisplatin up-
take by these cells30. Thus, renal Ctr1 expression might be 
responsible for cisplatin-induced tubular toxicity. In addi-
tion, several reports suggest that organic cation transporters 
(Oct), specifically Oct2, are involved in the uptake of cispla-
tin in renal tubular cells. Ciarimboli et al.31 confirmed that 
Table 1.  Toxicity Target and Histopathological Characteristics in Cisplatin and Nedaplatin-induced Nephrotoxicity in Rats
Compounds Toxicity target in the kidney Histopathology
Cisplatin Proximal tubule, straight (S3 
segment) in the outer medul-
lary stripe
Necrosis (degeneration), apoptosis and regeneration of the renal proxi-
mal tubule; tubular dilatation; inflammatory cells infiltration; fibrosis 
(chronic)
Nedaplatin Renal papilla (collecting 
duct, epithelium covering the 
papilla)
Papillary necrosis (severe case only); hyaline droplet (enlarged lyso-
somes), necrosis (degeneration), apoptosis and regenerative hyperplasia 
of the collecting duct epithelium and the epithelium covering the renal 
papilla; tubular dilatation; with slightly affected proximal and distal 
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human Oct2 is responsible for basolateral uptake of cisplatin 
in the kidney. Yonezawa et al.32 determined that in HEK293 
cells stably expressing rat Oct2, renal Oct2 expression is 
the major determinant of cisplatin-induced tubular toxicity. 
Filipski et al.33 provided evidence that Oct1/Oct2-deficient 
mice are protected from renal tubular damage caused by cis-
platin. Subsequently, they found that a nonsynonymous sin-
gle-nucleotide polymorphism in the Oct2 gene is associated 
with reduced cisplatin-induced nephrotoxicity in humans.
Information regarding the mechanisms involved in the 
cellular uptake of nedaplatin is relatively limited. However, 
there is clear evidence that in both humans and rats, neda-
platin, which is less nephrotoxic than cisplatin, does not in-
teract with Oct2 or the apical multidrug and toxin extrusion 
transporter  (MATE)  family  of  proteins34,35.  The  reduced 
nephrotoxicity of nedaplatin might therefore be associated 
with reduced accumulation in the proximal tubules due to 
its lower affinity for transporters, including Oct2 and the 
MATE family. Tanaka et al.36 reported that 10 min after a 
single intravenous dose of radiolabeled nedaplatin, the high-
est radioactivity is found in the kidney, particularly in the 
cortex and papilla. After 1 h, the highest radioactivity is 
observed in the papilla. Differences in the primary site of 
injury in the kidney may therefore be partially attributed to 
differences in the renal kinetics of cisplatin and nedaplatin. 
In addition, histopathological differences may be due to dif-
ferences in the transporter systems involved, but additional 
studies are needed to resolve this question.
Molecular pathogenesis of cisplatin nephrotoxicity
Oxidative  stress  is  one  of  the  main  mechanisms  of 
cisplatin nephrotoxicity37. Various reactive oxygen species 
(ROS) are produced by cisplatin treatment in cultured renal 
tubular cells, kidney slices and in vivo in the kidney. Sev-
eral possible mechanisms have been proposed to account 
for ROS generation under the pathological conditions of cis-
platin nephrotoxicity. After being incorporated into a cell, 
cisplatin is transformed to a highly reactive form, which 
then rapidly reacts with antioxidants including glutathione. 
However, under conditions in which there is excessive gen-
eration of the reactive form in a cell, glutathione and related 
antioxidants are depressed, leading to a change in the redox 
status and eventually resulting in the accumulation of en-
dogenous ROS. ROS in turn causes oxidative damage with-
in the cells38. In addition, mitochondrial dysfunction might 
be related to increased ROS production in cisplatin nephro-
toxicity due to disruption of the mitochondrial antioxidant 
defense system39. Although the molecular targets of ROS 
generated by cisplatin treatment are still largely unknown, 
ROS may react with multiple molecules in the cell, includ-
ing mitochondrial lipids and proteins, ultimately leading to 
cellular injury.
At the molecular level, several genes are known to be 
deregulated in the kidney by cisplatin treatment. Compre-
hensive  gene  expression  profiling  revealed  that  oxidative 
stress response genes are deregulated following 7-day cis-
platin treatment in rats. This includes upregulation of the 
gene  encoding  metallothionein  1  and  downregulation  of 
genes encoding catalase, superoxide dismutase and γ-GT40. 
Aleksunes et al.41 demonstrated the induction of cytopro-
tective genes/proteins following cisplatin treatment, includ-
ing NAD(P)H dehydrogenase, quinone 1, heme oxygenase 
1 (Hmox1) and glutamate cysteine ligase catalytic subunit, 
all of which are known to be induced by activation of the 
transcription factor Nrf2 (nuclear factor E2-related factor 
2). These changes in gene expression could be responsible 
for downstream cell death associated with oxidative stress-
mediated tubular injury in cisplatin nephrotoxicity. There 
is also some evidence suggesting that cisplatin treatment 
induces glutathione depletion in the kidney42 and that glu-
tathione supplementation attenuates cisplatin nephrotoxic-
ity43. Taken together, the available evidence indicates that 
oxidative stress plays an important role in the mechanism of 
cisplatin nephrotoxicity.
Excessive oxidative stress leads to the death of renal 
tubular cells as a result of cisplatin-induced cellular injury, 
which leads to tubular cell necrosis and apoptosis. Several 
apoptotic pathways have been implicated in this process, 
including the extrinsic pathway mediated by death recep-
tors,  the  endoplasmic  reticulum-stress  pathway  and  the 
mitochondrial-associated intrinsic apoptotic pathway12,44,45. 
In addition to the involvement of these apoptotic pathways, 
p21 is also known to play an important role in directing the 
switching of signals in renal tubular cells between survival 
cell death46,47. Both necrosis and apoptosis are reported to 
be induced in renal tubular cells in vivo48,49. This difference 
of phenotype in cisplatin-induced cellular injury can be ex-
plained by evidence demonstrating that exposure to high 
concentrations of cisplatin lead to necrotic cell death, while 
exposure to much lower concentrations result in apoptosis50. 
Furthermore, it has also been determined that ROS play a 
role in mediating apoptosis but not necrosis following cis-
platin exposure50. Thus, the mechanism of cisplatin-induced 
renal tubular necrosis is thought to be concentration-depen-
dent.
Molecular pathogenesis of nedaplatin nephrotoxicity
Application of toxicogenomics is a promising strategy 
to determine the molecular mechanisms underlying chemical 
toxicity and to aid in the early detection of toxic effects51–54. 
Recently, our laboratory conducted a toxicogenomic study 
to  broaden  understanding  of  the  cellular  and  molecular 
mechanisms involved in nedaplatin nephrotoxicity50. Using 
DNA microarrays, gene expression profiles were analyzed 
in two renal regions, the cortex and papilla, following ad-
ministration of a single dose of nedaplatin in rats. We found 
striking similarities in the gene expression profiles between 
the renal cortex and papilla. More specifically, we found that 
several genes belonging to various functional categories are 
deregulated in both renal regions in accordance with histo-
pathological changes associated with nedaplatin nephrotox-
icity (Fig. 1). Upregulated genes include those involved in 
apoptosis, cell cycle regulation, DNA metabolism, cell mi-
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stress, while genes reflecting renal malfunction, including 
calcium homeostasis, are downregulated. One of the major 
histopathological changes associated with nedaplatin neph-
rotoxicity is apoptosis in renal tubules. Upregulation of my-
elocytomatosis  viral  oncogene  homolog,  death-associated 
protein, tribbles homolog 3 and TNF receptor superfamily 
member 6 in nedaplatin nephrotoxicity is thought to be re-
lated to apoptotic cell death. In addition, we also observed 
that the expression of various oxidative stress responsive 
genes, including Hmox1, metallothionein 1a, glutaredoxin 
1 and glutathione S-transferase mu 1, is enhanced, as is the 
case in cisplatin nephrotoxicity. The Hmox1 gene encodes 
the rate-limiting enzyme in the degradation of heme55, and 
protects against oxidative stress56,57. Metallothioneins play 
a role in the detoxification of toxic metals and in protection 
against oxidative stress58–60. Glutaredoxins are thiol oxido-
reductases that use reduced glutathione as a hydrogen donor 
to reduce protein disulfides or glutathione–protein-mixed 
disulfides in a coupled system with glutathione reductase 
and NADPH61,62. Glutathione S-transferase, a member of 
the phase II group of xenobiotic metabolizing enzymes, is 
known to conjugate reactive compounds to glutathione prior 
to their excretion from the body63, and also acts as a gluta-
thione peroxidase, converting lipid peroxides to the hydrox-
yl form and oxidizing reduced glutathione63. On the basis of 
these observations, we concluded that nedaplatin treatment 
affects both the renal papilla and cortex through oxidative 
stress-related mechanisms.
Our research also provided novel evidence indicating 
that cytokeratin subtypes 14 and 19 are overexpressed in 
the papilla following nedaplatin treatment50. Distinct posi-
tive expression of cytokeratins 14 and 19 was specifically 
localized to the epithelium covering the papilla and/or the 
collecting duct epithelium. Cytokeratins, which are a di-
verse group of intermediate filament proteins, are known to 
play a critical role in differentiation and tissue specialization 
and function in the maintenance of epithelial cell structural 
integrity. The wide acceptance of cytokeratins as excellent 
epithelial cell markers is largely related to the differentia-
tion-specific expression patterns shown by individual iso-
types64–66. Cytokeratin 14 is expressed in the basal and first 
suprabasal layers of various stratified squamous epithelia, 
but not in simple epithelial cells67. Cytokeratin 19 is a major 
component of simple epithelia in a wide range of epithelial 
tissues64. In nedaplatin-induced renal papillary toxicity, in-
creased expression of cytokeratins 14 and 19 might reflect 
Fig. 1.  Putative cellular pathways of nedaplatin nephrotoxicity. This schematic pathway was assembled using gene expression data 
obtained from nedaplatin-treated rat kidneys 6 days after a single dosing. Upregulation and downregulation are represented 
by ↑ or ↓, respectively.Uehara, Yamate, Torii et al. 91
abnormal squamous differentiation of the epithelium cover-
ing the renal papilla and regeneration related to the repair 
process of the injured epithelial cells in the collecting duct.
Amelioration of Nedaplatin Nephrotoxicity
As described above, nedaplatin has the potential to af-
fect the entire nephron, with characteristic papillary injury 
occurring where the drug concentration reaches maximum 
levels46,48. Hydration is thought of as a promising approach 
for  ameliorating  cisplatin  nephrotoxicity  because  it  pro-
motes excretion of the drug into the urine and dilutes the 
drug concentration in the urine by causing polyuria7,11,68. 
We evaluated whether hydration before dosing does in fact 
ameliorate nedaplatin nephrotoxicity. We found that hydra-
tion dramatically reduces nedaplatin nephrotoxicity, but has 
no clear effect on myelotoxicity. Measurement of urinary 
platinum excretion revealed that the total amount of plati-
num excreted is significantly higher in hydrated rats than in 
nonhydrated rats. In terms of the urinary nedaplatin concen-
tration, hydrated rats have a lower concentration compared 
with nonhydrated rats. Hydration at the time of nedaplatin 
dosing could therefore be an effective strategy for minimiz-
ing nephrotoxicity.
We  also  examined  the  usefulness  of  prolonging  the 
infusion  time  for  reducing  nephrotoxicity  resulting  from 
nedaplatin treatment69. This study provided evidence that 
prolonging  the  infusion  time  effectively  minimizes  the 
nephrotoxicity associated with nedaplatin. This effect may 
be related to a reduction in the maximal drug concentration 
in circulating blood, which consequently reduces the con-
centration of drug in the nephron. Because nedaplatin and 
cisplatin have similar nephrotoxic mechanisms, nedaplatin 
nephrotoxicity may be limited by cotreatment with antioxi-
dants, although the capacity of antioxidants to ameliorate 
nedaplatin nephrotoxicity has not been studied.
Usefulness of Animal Models of Renal Failure 
Using Differences Between Cisplatin- and Neda-
platin-Induced Lesions
Because  cisplatin  specifically  injures  the  proxi-
mal  tubule,  several  studies  have  used  this  drug  to  elu-
cidate  the  pathophysiological  mechanisms  involved  in 
the  development  of  nephrotoxicity.  The  chronic  cis-
platin  nephrotoxicity  experimental  model  provides 
particularly  useful  insights  into  the  detailed  mecha-
nisms  underlying  chronic  renal  failure  and  exhibits   
pathologic features similar to those seen with human lesions. 
Interestingly, the rat cisplatin-induced chronic nephrotoxic-
ity model showed that interactions between different macro-
phage populations play an important role in the development 
of renal interstitial fibrosis70–73. Recently, it was reported 
that epithelial-mesenchymal transition of tubular epithelial 
cells contributes significantly to the development of renal fi-
brosis. The cisplatin nephrotoxicity model was used to con-
firm that prostaglandin E2, derived from activation of cy-
clooxygenase-1, may regulate renal epithelial regeneration 
via the prostaglandin E2 receptor EP4 through inhibition 
of apoptosis and epithelial-mesenchymal transition74. Com-
paratively little research has focused on the pathophysiology 
of chronic nephrotoxicity using the nedaplatin nephrotoxic-
ity model. Further studies using this model may enhance 
understanding of the mechanisms leading to chronic renal 
failure and progressive fibrosis in humans, especially with 
respect to renal papillary injury with metaplastic changes in 
the papillary epithelium. These efforts may lead to the de-
velopment of a novel therapeutic strategy for chronic renal 
failure in humans.
Conclusions
Although reduced nephrotoxicity compared with cis-
platin  makes  nedaplatin  a  promising  second-generation 
platinum complex, this drug may also cause nephrotoxicity 
at doses that are therapeutic in humans, especially in the 
case of patients with deteriorated renal function. Histopath-
ologically,  nedaplatin  nephrotoxicity  in  rats  is  character-
ized by apoptosis and/or necrosis, subsequent regeneration 
and cystic dilatation, not only in the proximal tubule but 
also in the distal tubule and the collecting duct. In severe 
cases, papillary necrosis also occurs. Comprehensive gene 
expression profiling revealed that nedaplatin nephrotoxic-
ity might be induced by oxidative stress-mediated mecha-
nisms. Furthermore, several genes have been identified as 
being specifically deregulated. Deregulation of the genes 
encoding cytokeratins 14 and 19 reflects the characteristic 
renal papillary injury associated with nedaplatin. Overall, 
recent research has provided significant insights into the 
molecular and histopathological events that are responsible 
for nedaplatin nephrotoxicity. These insights could lead to 
the establishment of an effective strategy for the safe use of 
nedaplatin in humans.
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